Form 4: COO Nieuwkoop Gains Shares Post-Hyperliquid Merger

Hyperliquid Strategies Inc. COO Jeroen Nieuwkoop received 31,840 common shares following the company's business combination.

Summary

• Jeroen Nieuwkoop, Chief Operating Officer of Hyperliquid Strategies Inc., acquired 31,840 shares of the company's common stock.
• The acquisition occurred on December 4, 2025, as a distribution from Rorschach Capital LLC.
• This distribution followed the completion of a previously announced business combination on December 2, 2025.
• The business combination involved Hyperliquid Strategies Inc., Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC, TBS Merger Sub Inc., and Rorschach Merger Sub, LLC.
• In connection with the closing of the business combination, Rorschach Capital LLC received an aggregate of 6,580,800 shares of Hyperliquid Strategies Inc. common stock.

Sentiment

Score: 7

Explanation: The filing indicates a successful completion of a business combination and an increase in insider ownership, which is generally positive. However, it's a routine disclosure of a transaction rather than a performance report, limiting its direct impact on sentiment.

Positives

• Chief Operating Officer Jeroen Nieuwkoop increased his direct beneficial ownership by 31,840 shares of common stock, signaling potential confidence.
• The company successfully completed a previously announced business combination on December 2, 2025, indicating a significant strategic milestone.

Future Outlook

This filing, a Form 4, primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This insider transaction follows a significant corporate event, a business combination, indicating the integration phase where equity is distributed to key personnel or entities involved. While the specific industry details are not elaborated in this filing, the completion of such a combination suggests strategic realignment and potential growth opportunities for Hyperliquid Strategies Inc. within its market.

Related Party Transactions

• Jeroen Nieuwkoop, Chief Operating Officer of Hyperliquid Strategies Inc. and a member of Rorschach Capital LLC, received 31,840 shares of common stock from Rorschach Capital LLC. This distribution occurred following the completion of a business combination where Rorschach Capital LLC received a substantial number of shares.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive (COO) post-merger can be viewed positively, signaling management's alignment with shareholder interests and confidence in the combined entity's future. The underlying business combination itself has broader implications for the company's strategic direction and potential value creation.
• Employees: No direct impact on employees is mentioned in this transaction report.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned in this transaction report.

Key Dates

Keywords

Hyperliquid Strategies Inc, PURR, Jeroen Nieuwkoop, Chief Operating Officer, Common Stock, Share Acquisition, Business Combination, Sonnet BioTherapeutics, Rorschach Capital LLC, Insider Transaction, Form 4